We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ARAB HEALTH - INFORMA

Download Mobile App




Smartphone Technology Meets Personalized Medicine

By HospiMedica International staff writers
Posted on 14 Mar 2012
An innovative smartphone electrocardiogram (ECG) system provides physicians and patients with hospital-quality heart rhythm monitoring outside of the hospital setting. More...


The CardioDefender Diagnostic System delivers mobile heart monitoring and automated reporting by combining patented analytical smartphone software with a Bluetooth device and electrodes, enabling the smartphone to perform as a mobile ECG. Among the features of the system are real-time, heart-rhythm monitoring, with beat-by-beat analysis; long term monitoring for up to three months of real-time, beat-by-beat quantitative patient monitoring; and a comprehensive range of heart rhythm monitoring algorithms that enable automated detection and reporting of medically important symptomatic and asymptomatic arrhythmias.

The abnormal heart rhythms are reported directly to the physician, using innovative software and data compression technology to report real-time results to a smartphone, tablets, laptop, or desktop computer, in addition to a cardiac monitoring center. Access is available on demand to full, detailed ECG data captured during the monitoring period, including post heart monitoring data processing for additional measurements. The CardioDefender Diagnostic System is a product of Everist Genomics (Ann Arbor, MI, USA), and has been approved by the US Food and Drug Administration (FDA).

“Physicians who diagnose and treat heart arrhythmias have been hampered for many years by legacy technology, such as hospital based ECG systems which confine patients to the high-cost hospital setting and Holter monitors which do not provide the comprehensive monitoring needed to detect potentially life threatening arrhythmias,” said Alex Charlton, executive vice chairman of Everist Genomics. “For the first time, CardioDefender enables smartphone-based hospital-quality ECG monitoring of patients 24 hours per day, seven days per week.”

In addition to the CardioDefender diagnostic system, the company has recently announced the development of the AngioDefender, a tablet computer device capable of accurately diagnosing atherosclerosis in asymptomatic patients.

Related Links:
Everist Genomics


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammo DR Retrofit Solution
DR Retrofit Mammography
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image:The biotechnology market in the GCC is projected to reach $2.6 billion by 2028, with the UAE and Saudi Arabia leading the growth in the region (Photo Courtesy of Infroma Markets)

WHX in Dubai (formerly Arab Health) to debut specialised Biotech & Life Sciences Zone as sector growth accelerates globally

World Health Expo (WHX) in Dubai, formerly Arab Health, which takes place from 9-12 February 2026 at the Dubai Exhibition Centre (DEC), has officially announced the launch of a new dedicated Biotech &... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.